MYRIAD GENETICS INC (MYGN)       20.93  +0.59 (+2.9%)

20.93  +0.59 (+2.9%)

US62855J1043 - Common Stock - After market: 20.93 0 (0%)


Fundamental Rating

4

Overall MYGN gets a fundamental rating of 4 out of 10. We evaluated MYGN against 634 industry peers in the Biotechnology industry. Both the profitability and the financial health of MYGN get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, MYGN is valued expensive at the moment.




Profitability

Profitability Rating

6

MYGN has a Return On Assets of -6.38%. This is amongst the best returns in the industry. The industry average is -44.83%. MYGN outperforms 89% of its industry peers.
MYGN has a Profit Margin of -11.69%. This is amongst the best returns in the industry. The industry average is -464.10%. MYGN outperforms 84% of its industry peers.

The Piotroski-F score of MYGN is 4.00. This is a neutral score and indicates average health and profitability for MYGN.
MYGN has negative profitability rations, so we won't be analyzing them here.
VS Industry

ROA (-6.38%) VS Industry: 89% outperformed.

-3,944.82
115.38

Profit Margin (-11.69%) VS Industry: 84% outperformed.

-1,173,705.71
34,743.00

Valuation

Valuation Rating

1

When comparing the current price to the book value of MYGN, we can conclude it is valued correctly. It is trading at 1.85 times its book value.
When comparing the price book ratio of MYGN to the average industry price book ratio of 1.73, MYGN is valued in line with its industry peers.

MYGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Forward Price/Earnings Ratio of 143.16, MYGN is valued very expensively.
VS Industry

Price/Book (1.85) VS Industry: 47% outperformed.

134.78
0.10

Growth

Growth Rating

4

Based on estimates for the next 5 years, MYGN will show a very strong growth in Earnings Per Share. The EPS will grow by 155.33% on average per year.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
The Revenue has decreased by -3.36% in the past year.

The Revenue has been decreasing by -1.39% on average over the past 5 years.
Based on estimates for the next 5 years, MYGN will show a small growth in Revenue. The Revenue will grow by 3.02% on average per year.
The earnings per share for MYGN have decreased strongly by -150.00% in the last year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -150% -389.02% 170.37% 161.51% 155.33%
Revenue-1.39% -2.44% -3.36% 0.58% 3.66% 4.28% 3.02%

Health

Health Rating

6

A Current Ratio of 2.73 indicates that MYGN has no problem at all paying its short term obligations.
MYGN has a Quick Ratio of 2.58. This indicates that MYGN is financially healthy and has no problem in meeting its short term obligations.
MYGN has an Altman-Z score of 3.68. This indicates that MYGN is financially healthy and little risk of bankruptcy at the moment.
The Altman-Z score of MYGN is much better than the industry average of -0.65.

The Debt to Equity ratio of MYGN is in line with the industry averages.
MYGN has a Piotroski-F score of 4.00. This indicates an average health and profitability for MYGN.
Compared to an average industry Current Ratio of 6.11, MYGN is worse placed to pay its short term obligations than its industry peers.
When comparing the Quick Ratio of MYGN to the average industry Current Ratio of 6.02, MYGN is less able to pay its short term obligations than its industry peers.
VS Industry

Debt/Equity (0) VS Industry: 41% outperformed.

15.37
0.00

Quick Ratio (2.58) VS Industry: 22% outperformed.

0.02
84.53

Current Ratio (2.73) VS Industry: 22% outperformed.

0.02
85.09

Altman-Z (3.68) VS Industry: 72% outperformed.

-1,822.12
441.73

Dividend

Dividend Rating

0

MYGN does not give a dividend.

MYGN Daily chart

MYRIAD GENETICS INC20.93

NASDAQ:MYGN (12/2/2022, 7:00:01 PM)+0.59 (+2.9%)

After market: 20.93 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-15 2022-11-15/bmo Earnings (Next) N/A N/A
Ins Owners 4.02% Inst Owners 98.27%
Market Cap 1.70B Analysts 47.14
Valuation
PE N/A Fwd PE 143.16
PEG (NY) N/A PEG (5Y) N/A
P/S 2.56 P/B 1.85
EV/EBITDA -218.51
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -150% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -850%
EPS Next Y -389.02% EPS Next 2Y 170.37%
EPS Next 3Y 161.51% EPS Next 5Y 155.33%
Revenue growth 1Y -3.36% Revenue growth 3Y -2.44%
Revenue growth 5Y -1.39% Revenue growth Q2Q -6.52%
Revenue Next Year 0.58% Revenue Next 2Y 3.66%
Revenue Next 3Y 4.28% Revenue Next 5Y 3.02%
Health
Current Ratio 2.73 Quick Ratio 2.58
Altman-Z 3.68 F-Score 4
Debt/Equity 0 WACC 9.03%
ROIC/WACC N/A
Profitability
ROA -6.38% ROE N/A
ROICexgc N/A ROIC N/A
PM -11.69% OM -8.89%
Asset Turnover 0.55

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA